Phase II Study of Olaparib and Temozolomide for Advanced Uterine Leiomyosarcoma (NCI Protocol 10250)

医学 奥拉帕尼 替莫唑胺 内科学 肿瘤科 中性粒细胞减少症 临床终点 临床研究阶段 化疗 外科 临床试验 生物化学 聚合酶 基因 聚ADP核糖聚合酶 化学
作者
Matthew Ingham,Jacob B. Allred,Li Chen,Biswasjit Das,Bose Kochupurakkal,Katherine Gano,Suzanne George,Steven Attia,Melissa Burgess,­Mahesh Seetharam,Sosipatros A. Boikos,Nam Q. Bui,James L. Chen,Julia Close,Gregory M. Coté,Premal H. Thaker,S. Percy Ivy,Sminu Bose,Alan D. D’Andrea,Adrián Mariño‐Enríquez
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:41 (25): 4154-4163 被引量:33
标识
DOI:10.1200/jco.23.00402
摘要

PURPOSE Uterine leiomyosarcoma (uLMS) is an aggressive subtype of soft-tissue sarcoma with frequent metastatic relapse after curative surgery. Chemotherapy provides limited benefit for advanced disease. Multiomics profiling studies have identified homologous recombination deficiency in uLMS. In preclinical studies where olaparib and temozolomide provided modest activity, the combination was highly effective for inhibiting uLMS tumor growth. PATIENTS AND METHODS NCI Protocol 10250 is a single-arm, open-label, multicenter, phase II study evaluating olaparib and temozolomide in advanced uLMS. Patients with progression on ≥1 prior line received temozolomide 75 mg/m 2 orally once daily with olaparib 200 mg orally twice a day both on days 1-7 in 21-day cycles. The primary end point was the best objective response rate (ORR) within 6 months. A one-stage binomial design was used. If ≥5 of 22 responded, the treatment would be considered promising (93% power; α = .06). All patients underwent paired biopsies that were evaluated with whole-exome sequencing (WES)/RNAseq and a RAD51 foci formation assay. RESULTS Twenty-two patients were evaluable. The median age was 55 years, and 59% had received three or more prior lines. Best ORR within 6 months was 23% (5 of 22). The overall ORR was 27% (6 of 22). The median progression-free survival (mPFS) was 6.9 months (95% CI, 5.4 months to not estimable). Hematologic toxicity was common (grade 3/4 neutropenia: 75%; thrombocytopenia: 32%) but manageable with dose modification. Five of 16 (31%) of tumors contained a deleterious homologous recombination gene alteration by WES, and 9 of 18 (50%) were homologous recombination-deficient by the RAD51 assay. In an exploratory analysis, mPFS was prolonged for patients with homologous recombination-deficient versus homologous recombination-proficient tumors (11.2 v 5.4 months, P = .05) by RAD51. CONCLUSION Olaparib and temozolomide met the prespecified primary end point and provided meaningful clinical benefit in patients with advanced, pretreated uLMS.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
烟花的应助被Qianfan采纳,获得10
刚刚
刚刚
酷波er的应助被野酒采纳,获得10
刚刚
寒烟完成签到,获得积分10
刚刚
胖头鱼发布了新的文献求助10
刚刚
3秒前
4秒前
白白不是球完成签到,获得积分10
4秒前
yyyyy发布了新的文献求助30
4秒前
害怕的穆发布了新的文献求助10
4秒前
chilin发布了新的文献求助10
5秒前
Maestro_S的应助被神奇蜥蜴采纳,获得10
5秒前
无极微光的应助被烂漫的灰狼采纳,获得20
5秒前
王海祥完成签到 ,获得积分10
6秒前
包容的飞丹完成签到,获得积分10
7秒前
chcuifv完成签到 ,获得积分10
7秒前
快乐如云朵完成签到 ,获得积分10
7秒前
RichardGuo完成签到 ,获得积分10
7秒前
李健的小迷弟的应助被hepote采纳,获得10
7秒前
友好小刺猬完成签到,获得积分10
8秒前
六六完成签到,获得积分10
8秒前
tcy露完成签到,获得积分10
9秒前
9秒前
10秒前
11秒前
可可完成签到,获得积分10
12秒前
12秒前
yofaz完成签到,获得积分10
12秒前
宁静致远完成签到,获得积分10
12秒前
12秒前
苹果画板发布了新的文献求助10
12秒前
JamesPei的应助被缓慢绿草采纳,获得10
13秒前
Ava的应助被郗XI采纳,获得10
13秒前
六六发布了新的文献求助30
13秒前
852的应助被贾文浩采纳,获得10
13秒前
13秒前
Owen的应助被精明机器猫采纳,获得10
13秒前
13秒前
在研究里遨游的小鱼完成签到,获得积分10
14秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8168144
求助须知:如何正确求助?哪些是违规求助? 9561199
关于积分的说明 21759542
捐赠科研通 7759434
什么是DOI,文献DOI怎么找? 3429948
关于科研通互助平台的介绍 2553742
邀请新用户注册赠送积分活动 2474463